Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand

References

• Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007;25:90-7
   Google Scholar
• Narenpitak S, Narenpitak A. Prevalence of chronic kidney disease in type 2 diabetes in primary health care unit of Udon Thani province, Thailand. J Med Assoc Thailand = Chotmaihet thangphaet 2008;91:1505-13
   PubMedGoogle Scholar
• Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature review of the burden, costs, and outcomes. Globalization Health 2013;9:11
   PubMed Web of Science ®Google Scholar
• Ngarmukos C, Bunnag P, Kosachunhanun N, et al. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thailand =  Chotmaihet thangphaet 2006;89 (Suppl 1):S37-S42
   Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49 (Suppl 2):S1-S180
   Google Scholar
• Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-5
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thailand =  Chotmaihet thangphaet 2014;97 (Suppl 5):S50-S8
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20 (Suppl 1):S5-S26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20 (Suppl 1):S27-S40
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-43
   PubMed Web of Science ®Google Scholar
• World Health Organization. Life tables by country: Thailand; 2014. http://apps.who.int/gho/data/?theme=main&vid =61640. Accessed October 15, 2014
   Google Scholar
• Aekplakorn W, Srivanichakorn S, Sangwatanaroj S. Microalbuminuria and metabolic risk factors in patients with type 2 diabetes in primary care setting in Thailand. Diabetes Res Clin Pract 2009;84:92-8
   PubMed Web of Science ®Google Scholar
• National Statistical Office. Health; 2007. http://web.nso.go.th/en/survey/bts/datafiles/560619_09_Health.pdf. Accessed October 15, 2014
   Google Scholar
• Thamarangsi T. The situation of alcohol beaverage consumption and impact in Thailand 2013. Center for Alcohol Studies, International Health Policy Program, Bangkok: Ministry of Public Health; 2013
   Google Scholar
• Nitiyanant W, Chetthakul T, Sang-A-kad P, et al. A survey study on diabetes management and complication status in primary care setting in Thailand. J Med Assoc Thailand = Chotmaihet thangphaet 2007;90:65-71
   PubMedGoogle Scholar
• Supapluksakul S, Ruamviboonsuk P, Chaowakul W. The prevalence of diabetic retinopathy in Trang province determined by retinal photography and comprehensive eye examination. J Med Assoc Thailand = Chotmaihet thangphaet 2008;91:716-22
   PubMedGoogle Scholar
• The Endocrine Society of Thailand. Diabetes Registry Project 2003. Bangkok: Health Systems Research Institute; 2004
   Google Scholar
• Thaneerat T, Tangwongchai S. Prevalence of depression, hemoglobin A1c level, and associated factors in outpatients with type 2 diabetes. Asian Biomed (Res Rev News) 2009;3:383-90
   Google Scholar
• Maharaj Nakorn Chiang Mai Hospital. Pharmacy and Healthcare Service Fees. Chiang Mai: Maharaj Nakorn Chiang Mai Hospital; 2014
   Google Scholar
• Pornpinatepong S. Cost-effectiveness analysis of diabetic retinopathy screening in type2 diabetes mellitus [Master Thesis]. Bangkok: Mahidol University; 2005
   Google Scholar
• Riewpaiboon A. Standard cost lists for health technology assessment. Nonthaburi: Health Intervention and Technology Assessment Program (HITAP); 2011
   Google Scholar
• Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007;10:61-72
   PubMed Web of Science ®Google Scholar
• King Chulalongkorn Memorial Hospital. Pharmacy and Healthcare Service Fees. Bangkok: King Chulalongkorn Memorial Hospital; 2014
   Google Scholar
• National Health Security Office. Schedule of Health Benefits and Fees. Bangkok: National Health Security Office; 2014
   Google Scholar
• Russo E, Penno G, Prato SD. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013;6:161-70
   PubMedGoogle Scholar
• Arjona-Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013;61:579-87
   PubMed Web of Science ®Google Scholar
• Arjona-Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes care 2013;36:1067-73
   PubMed Web of Science ®Google Scholar
• Chan JCN, Scott R, Arjona-Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther 2014;5:1-41
   PubMed Web of Science ®Google Scholar
• Chan SP, Ji LN, Nitiyanant W, et al. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific: Real-life effectiveness and care patterns of diabetes management: The RECAP-DM study. Diabetes Res Clin Pract 2010;89:e30-2
   PubMedGoogle Scholar
• Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thailand = Chotmaihet thangphaet 2014;97 (Suppl 5):S17-S26
   PubMedGoogle Scholar
• Bureau of Trade and Economics Indices, Ministry of Commerce. CPI; 2016. www.price.moc.go.th/price/cpi/index_new_e.asp. Accessed July 8, 2016
   Google Scholar
• Bank of Thailand. Foreign exchange rates; 2015. https://www.bot.or.th/english/statistics/financialmarkets/exchangerate/_layouts/application/exchangerate/ExchangeRate.aspx. Accessed February 11, 2016
   Google Scholar
• Drug and Medical Supply Information Center; 2015]. http://dmsic.moph.go.th. Accessed April 15, 2016
   Google Scholar
• Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res 2013;5:29-36
   PubMedGoogle Scholar
• Geng J, Yu H, Mao Y, et al. Cost-effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics 2015;33:581-97
   PubMed Web of Science ®Google Scholar
• Bergenheim K, Williams SA, Bergeson JG, et al. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am J Pharm Benefits 2012;4:20-8
   Google Scholar
• Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev 2013;3:11
   PubMedGoogle Scholar
• Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012;32:189-202
   PubMed Web of Science ®Google Scholar
• Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes 2012;6:127-36
   PubMed Web of Science ®Google Scholar
• Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(Suppl1):43-55
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-97
   PubMed Web of Science ®Google Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-53
   PubMed Web of Science ®Google Scholar
• Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110:826-33
   PubMed Web of Science ®Google Scholar